EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Intravenous Ferric Carboxymaltose in Ischemic vs Nonischemic Heart Failure and Iron Deficiency: Insights From FAIR-HF2

Muhammad Shahzeb Khan, Javed Butler, Mahir Karakas, Marius Placzek, Gerd HASENFUß, Khawaja M Talha, Antoni Bayes-Genis, Andrew J S Coats, Michael Böhm, Giuseppe Rosano, Gianluigi Savarese, Markus S Anker und 3 weitere

Journal of Cardiac Failure · 2025

DOI: 10.1016/j.cardfail.2025.09.017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2025. Verfasst von Muhammad Shahzeb Khan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA; Baylor Scott and White Health-The Heart Hospital, Plano, T…. Hauptthemen laut MEDLINE: Ferric Compounds, Heart Failure, Maltose, Myocardial Ischemia. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous studies have suggested that patients with ischemic etiology of heart failure (HF) and iron deficiency may derive greater benefits from intravenous ferric carboxymaltose (FCM). We aim to assess the effects of FCM vs placebo in patients with ischemic vs nonischemic etiology of HF. METHODS AND RESULTS: The FAIR-HF2 trial included 1105 patients with HF, with a left-ventricular ejection fraction ≤ 45% and concomitant iron deficiency. Patients were randomized 1:1 to either intravenous FCM or placebo. Ischemic etiology was defined as investigator-reported or prior coronary revascularization or myocardial infarction. The primary endpoints were time-to-first-event of cardiovascular death or hospitalization due to HF, total HF hospitalizations, and time-to-first event of cardiovascular death or HF hospitalization in patients with transferrin saturation < 20% at baseline. Of 1105 patients, 858 (78%) had ischemic etiologies of HF. They were more commonly older and male and had more comorbidities. For the first primary endpoint, FCM was associated with a hazard ratio (HR) of 0.85 (95%CI: 0.66-1.10; P = 0.23) for ischemic HF and 0.61 (95% CI: 0.39-0.98; P = 0.038) for nonischemic HF (P-interaction = 0.26). The HR for the second primary endpoint was 0.87 (95% CI: 0.63-1.21, P = 0.41) for ischemic HF and 0.57 (95% CI: 0.35-0.94; P = 0.028) for nonischemic HF (P-interaction = 0.17), while HR for the third primary endpoint was 0.84 (95% CI: 0.62-1.14; P = 0.27) for ischemic HF and 0.63 (95% CI: 0.37-1.07; P = 0.087) for nonischemic HF (P-interaction = 0.35). CONCLUSIONS: The effect of intravenous iron supplementation is likely to be similar in patients with ischemic or nonischemic etiology of HF, just like other HF guideline-directed medical therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric CompoundsHeart FailureMaltoseMyocardial IschemiaAnemia, Iron-DeficiencyHumansMaleFemaleAgedDouble-Blind MethodMiddle AgedTreatment OutcomeStroke VolumeAdministration, Intravenous

Stichwörter der Autor:innen

FAIR-HF2, Intravenous Iron in Patients with Systolic Heart Failure and Iron Def…FCM, ferric carboxymaltoseHF, heart failureHeart failure, etiology, iron deficiency, ferric carboxymaltoseTSAT, transferrin saturation

Substanzen

Ferric Compoundsferric carboxymaltoseMaltose

Autor:innen und Institutionen

  • Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA; Baylor Scott and White Health-The Heart Hospital, Plano, TX, USA; Department of Medicine, Baylor College of Medicine, Temple, TX…
  • Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, TX, USA; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
  • Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany.
  • Department of Medical Statistics, University Medical Center Göttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany.
  • Clinic for Cardiology and Pneumology, University Medical Center Göttingen, German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Göttingen, Germany.
  • Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Zitieren

APA

Khan, M. S., Butler, J., Karakas, M., Placzek, M., HASENFUß, G., Talha, K. M., Bayes-Genis, A., Coats, A. J. S., Böhm, M., Rosano, G., Savarese, G., Anker, M. S., Ponikowski, P., Friede, T., & Anker, S. D. (2025). Intravenous Ferric Carboxymaltose in Ischemic vs Nonischemic Heart Failure and Iron Deficiency: Insights From FAIR-HF2. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2025.09.017

Vancouver

Khan MS, Butler J, Karakas M, Placzek M, HASENFUß G, Talha KM, et al. Intravenous Ferric Carboxymaltose in Ischemic vs Nonischemic Heart Failure and Iron Deficiency: Insights From FAIR-HF2. Journal of Cardiac Failure. 2025. doi:10.1016/j.cardfail.2025.09.017

BibTeX
@article{Khan2025,
  author = {Khan, Muhammad Shahzeb and Butler, Javed and Karakas, Mahir and Placzek, Marius and HASENFUß, Gerd and Talha, Khawaja M and Bayes-Genis, Antoni and Coats, Andrew J S and Böhm, Michael and Rosano, Giuseppe and Savarese, Gianluigi and Anker, Markus S and Ponikowski, Piotr and Friede, Tim and Anker, Stefan D},
  title = {Intravenous Ferric Carboxymaltose in Ischemic vs Nonischemic Heart Failure and Iron Deficiency: Insights From FAIR-HF2},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  doi = {10.1016/j.cardfail.2025.09.017}
}
Kostenlos starten →